Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)

SHE:002390 Revenue

Guizhou Xinbang Pharmaceutical had revenue of 1.20B CNY in the quarter ending September 30, 2026, a decrease of -15.91%. This brings the company's total for the last twelve months to 5.02B, down -12.52% year-over-year. In the year 2025, Guizhou Xinbang Pharmaceutical had annual revenue of 5.62B, down -6.84%. That makes Guizhou Xinbang Pharmaceutical the 9,064th largest company in the world by revenue and 1,429th in China.

• Revenue (ttm): 5.02B
• Revenue Growth: -12.52%
• P/S Ratio: 1.11
• Revenue / Employee: 1.07M
• Employees: 4,702
• Market Cap: 5.56B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Distribution 4.21B 62.0%
• Medical Services 1.57B 23.2%
• Pharmaceutical Manufacturing 1.01B 14.9%
• Other Industries 2.00M 0.0%

By Geography

Chart

• Southwest 5.86B 86.2%
• East China 811.99M 11.9%
• North China 63.33M 0.9%
• Central China 35.28M 0.5%
• Northeast 10.95M 0.2%
• South China 9.89M 0.1%
• Northwest 5.12M 0.1%

Fiscal year ended Dec 31, 2025 See the full SHE:002390 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	5.62B	-412.70M	-6.84%
Dec 31, 2024	6.03B	-428.58M	-6.63%
Dec 31, 2023	6.46B	110.82M	1.75%
Jan 1, 2023	6.35B	-121.84M	-1.88%
Jan 1, 2022	6.47B	626.24M	10.71%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error